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Abstract
Background—This study examined a PERIOD3 (PER3) gene variable number tandem repeat 
polymorphism and chronotype as potential BrCA risk factors among Indian women.
Methods—This case-control study included sporadic, histologically confirmed BrCA cases 
(n=255) and controls (n=249) from India with data collection from 2010–2012.
Results—Women with the 4/5 or 5/5 PER3 genotype had a non-statistically significant 33% 
increased odds of BrCA. BrCA cases were more likely to have a morning (OR=2.43, 95% 
CI=1.23–4.81) or evening (OR=2.55, 95% CI=1.19–5.47) chronotype.
Conclusions—Findings are consistent with the possibility that extremes in chronotype may 
elicit circadian desynchronization, resulting in adverse health outcomes.
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Breast cancer (BrCA) is the most common cancer among urban Indian women (1). The 
estimated range of age-adjusted BrCA incidence in urban areas is ~25–33 per 100,000 
(~33% of the United States [US] rate), and ~9 per 100,000 in rural areas (1,2). The Mumbai 
population increased from 3 to 12 million from 1950 to 2000, and age-adjusted BrCA 
incidence increased from 14 to 21 per 100,000 (3). Factors related to the demographic and 
epidemiologic transition currently occurring in India may have contributed to these 
increases, particularly in urban areas. The Breast Cancer Genetics, Environment, and 
Lifestyle (BRCAGEL) study was implemented to examine behavioral and genetic BrCA risk 
factors in the Mumbai region.
Clock genes maintain reciprocal transcriptional-translational feedback loops that drive the 
molecular clock in the body’s master circadian pacemaker (suprachiasmatic nuclei [SCN]), 
and in most peripheral tissues (4,5). The SCN transduces ambient light into neuroendocrine 
and autonomic signals that synchronize physiological timekeeping in most major organs 
(4,5). Clock gene variation or dysregulation can impact the cardiovascular, digestive, 
endocrine, and central nervous systems, sleep-wake cycles, and cellular processes 
considered hallmarks of carcinogenesis (e.g., cell proliferation, DNA damage response, 
apoptosis) (5,6). For example, clock gene polymorphisms have been associated with sleep 
disorders, mood disturbances, chronotype and increased cancer risk in some studies (4,5,7–
10). Tumors among breast and other cancer patients have reduced PERIOD clock gene 
expression relative to adjacent normal tissue (5,11–14). This and other evidence suggests 
that PERIOD clock genes exert a tumor suppressor function (14–16). The PER3 variable 
number tandem repeat (VNTR, rs57875989) length polymorphism contains four or five 
copies of a 54-bp sequence encoding 18 amino acids (4,17). The 5-repeat sequence adds 
several potential phosphorylation sites, and PER3’s interaction with circadian processes may 
be enhanced among those with the 5/5 compared to the 4/4 genotype (9,18). This may render 
5/5 variants more susceptible to changes in sleep schedule or exposure to light-at-night 
(9,18). The 5/5 genotype has been associated with morningness (19–21) and with increased 
premenopausal BrCA risk (7). However, not all studies have been consistent (22–24), and 
the functional consequences of this polymorphism await further characterization.
Chronotype refers to an inherent, self-reported morning or evening preference (25,26). This 
trait has a 25–50% inheritance pattern (22,27,28), and it predicts intrinsic circadian period 
(29) sleep-wake timing, and other diurnal psychophysiological processes (5,25). Extremes in 
chronotype may elicit chronic sleep loss and circadian desynchronization, although few have 
investigated the potential health-related consequences. Impacts associated with eveningness 
tend to be more common, including associations with poor sleep, fatigue, depression, 
hypertension, and type II diabetes (30–32). However, morningness has been linked with 
sleep disruption, fatigue, lipid dysregulation and weight gain (32–39). Chronotype may also 
enhance cancer risk associated with shiftwork (40–42). Morning types tend to be less 
tolerant of shiftwork (43), and BrCA risks among morning types working nights (odds ratio 
[OR]=3.9, 95% confidence interval [CI]=1.6–9.5) were almost double those observed 
among evening types working nights (OR=2.0, 95% CI=0.7–5.8) (44). Others have reported 
no associations between BrCA and extreme chronotype, or with chronotype in combination 
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with shiftwork or sleep disruption, indicating a need for more research (45,46). Disparities 
between chronotype and social schedules can induce ‘social jetlag’ due to chronically 
desynchronized sleep-wake timing, even among non-shiftworkers (47). Such impacts have 
been associated with depressive symptoms and weight gain (47,48). Similarly, factors 
reducing psychosocial adaptability have been associated with a poor BrCA prognosis, 
although they have not been closely examined as potential cancer risk factors (49,50). 
Chronotype and the PER3 VNTR both have behavioral, physiological and genetic 
underpinnings that may foster circadian rhythm disruption and cancer susceptibility. This 
exploratory analysis tested the hypotheses that: woman with either the 4/5 or 5/5 PER3 
genotype, or women with a morning or evening preference, have an increased BrCA risk 
compared to women with a 4/4 genotype, or women with no circadian preference, 
respectively.
Methods and Materials
Women attending the Tata Memorial Hospital (TMH), which houses the largest oncology 
clinic in India, were recruited from TMH by the Advanced Center for Treatment, Research 
and Education in Cancer (ACTREC) staff, who also processed biospecimens and performed 
genotyping after receiving Institutional Review Board approval. Eligible cases included 
women <80 years old with histopathologically confirmed primary BrCA among patients 
undergoing treatment or within one year of post-treatment follow-up at the TMH. Patients 
were ineligible if they had: a previous cancer diagnosis (other than non-melanoma skin 
cancer), a concurrent cancer diagnosis at another anatomic site, or ductal carcinoma in situ. 
Control recruitment was conducted at TMH and was restricted to healthy women with no 
previous cancer diagnosis or active illness, including: non-blood relatives or spouses of male 
cancer patients, unrelated visitors of cancer patients, or women without BrCA signs or 
symptoms attending the Preventive Oncology unit for general cancer screening. Controls 
were frequency matched to cases on age (±5 years), geographic region, and menopausal 
status.
Participants provided informed consent, completed a detailed interview using a standardized 
questionnaire, and donated an oral mouthwash specimen or peripheral blood for DNA 
recovery via standardized phenol chloroform precipitation procedures (51). Trained 
interviewers ascertained sociodemographic (e.g., age, income, education, occupation, 
marital status, religion, residential and medical history) and known or potential BrCA risk 
factors (e.g., family cancer history, contraceptive use, pregnancies, live births, breast-
feeding duration and frequency, age of menarche and menopause, pesticide or household 
chemical use, ionizing radiation exposure, physical activity, diet, tobacco use, sleep 
behavior (52)). Body mass index (kg/m2) and waist-to-hip ratio (WHR) were obtained from 
clinic measurements. Cases and controls were recruited and interviewed at the same time of 
day. Chronotype and occupational items were adapted from the Standard Shiftwork Index 
(53). Less than 3% had ever worked nights; thus shiftwork was not evaluated. Items used to 
characterize chronotype included: ‘Some are morning types and some are evening types. 
What would you consider yourself to be?’ (responses: ‘Definitely a morning type’ [n=286, 
57%], ‘Rather more a morning type than an evening type’ [n=23, 5%], ‘Similar throughout 
the day’ [n=58, 12%], ‘Rather more an evening type than a morning type’ [n=80, 16%], and 
Wirth et al. Page 3













‘Definitely an evening type’ [n=55, 11%]). The ‘Rather morning’ and ‘Definitely morning’ 
categories were combined due to sparse data. To be consistent, the ‘Rather evening’ and 
‘Definitely evening’ groups also were combined. The other chronotype question was: ‘at 
what time of day do you usually feel your best?’ Responses to both questions were highly 
correlated and results in relation to BrCA status were similar; results using the first question 
are presented below.
The PER3 gene was amplified using previously described forward (5′-
TGGCAGTGAGAGCAGTCCT-3′) and reverse (5′-AGTGGCAGTAGGATGGGATG-3′) 
primers, and genotypes were established by sizing of polymerase chain reaction (PCR) 
products using gel electrophoresis (12% polyacrylamide) with ethidium bromide staining 
(7). The PCR conditions were: Cycle one, 95°C for 5 minutes; Cycle two (95°C for 45 
seconds, 58.8°C for 45 seconds, 72°C for 45 seconds) was repeated for 35 cycles. Reactions 
were then extended for 10 minutes at 72°C and terminated at 4°C. The 4- and 5-repeat 
sequences were recorded at 197bp and 257bp, respectively. Laboratory personnel were 
blinded to the identity and characteristics of the participants and each genotype was 
reviewed by two individuals with 100% concordance. The 4- and 5-repeat fragments were 
confirmed via sequencing, and quality control re-analysis yielded 100% concordance of 
genotype among 10% of the samples.
Data analyses were performed using the statistical analysis software package (SAS, version 
9.2, Cary, NC). Potential confounding factors were identified univariately (p≤0.15) and 
added to a ‘full’ model for further examination as confounders. Final models, which were 
derived from ‘full’ models, included age and all other variables that, when removed from the 
model, resulted in a 10% change in the OR for the primary exposure of interest, plus 
covariates that were statistically significant (p≤0.05). Unconditional fixed-effects logistic 
regression was used to calculate adjusted ORs among all women and in subgroups stratified 
by menopausal status, defined as those who reported no regular menses in at least 12 
months. Participants with the 4/5 (58%) or 5/5 (5%) genotype were combined for 
comparison with the 4/4 (38%) PER3 homozygotes (7,18,24). Ancillary analyses evaluated 
the relationship between PER3 genotype and BrCA status separately among women 
stratified by estrogen and progesterone receptor (ER, PR) status. In a previous study, women 
with ER/PR negative BrCA were more likely to have the 5-repeat PER3 genotype (24), thus 
similar analyses were performed in the current study, along with an assessment of ErbB2 
receptor status, and triple negative status (ER-, PR-, and ErbB2-). Since chronotype and the 
PER3 VNTR may both render individuals susceptible to circadian rhythm disruption or 
clock gene dysregulation, stratified analyses were also performed to examine the combined 
effects of PER3 genotype and chronotype.
Results
The study population consisted of 255 BrCA cases (recruitment rate: 77%) and 249 controls 
(recruitment rate: 73%). Most women had less than a high school education (80%), were 
married (88%), and refrained from tobacco use (89%). Their average age, income, and BMI 
were 46±10 years, 123±212 thousand rupees and 24.3±4.7 kg/m2, respectively. Controls 
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were more likely than cases to: be married, have an elevated income, refrain from tobacco 
use, and have a BMI >30 kg/m2 (Table 1).
The PER3 VNTR was characterized among 229 cases and 212 controls. Participants without 
PER3 genotype (n=64, 13%) were more likely to: live in a flat or house compared to a chawl 
(small apartment with shared bathrooms, OR=3.57, 95% CI=1.25–10.21), speak Hindi 
compared to Marathi (local Maharashtra language, OR=3.25, 95% CI=1.62–6.54), live in 
South or West India compared to Maharashtra (OR=2.24, 95% CI=1.23–4.10), and to have 
breastfed longer (OR=1.07, 95%CI=1.01–1.13) compared to those with PER3 VNTR data 
(n=441, 87%). Adjustment for these factors did not change the interpretation of the results 
presented below. PER3 VNTR frequencies (4/4: 38%, 4/5: 58%, 5/5: 5%) were not in 
Hardy–Weinberg equilibrium (HWE) among all participants (χ2=38.3, p<0.01) or among 
controls only (χ2=16.0, p<0.01). The observed frequencies were generally consistent with 
those reported previously (4/4: 35–74%, 4/5: 25–46%, 5/5: 2–18%) (7,24,54,55). BrCA 
cases were ~30–40% more likely to have the 4/5 or 5/5 genotype relative to controls, 
although the differences were not statistically significant (all women OR=1.33, 
95%CI=0.83–2.14; premenopausal OR=1.43, 95% CI=0.73–2.81; postmenopausal 
OR=1.31, 95%CI=0.63–2.73, Table 2). When stratified by ER/PR status, there were no 
notable differences in the relationship between PER3 genotype and BrCA odds among 
women with either ER/PR negative (OR=1.33, 95% CI=0.73–2.45) or ER/PR positive 
(OR=1.20, 95% CI=0.64–2.23) BrCA status. Additionally, the relationship between PER3 
genotype and BrCA did not differ among strata of ErbB2 or triple negative receptor status 
(data not shown).
Among all women, BrCA cases were more likely to have a morning (OR=2.43, 95% 
CI=1.23–4.81) or evening (OR=2.55, 95% CI=1.19–5.47, Table 2) chronotype compared to 
controls. This association was more predominant among post-menopausal relative to pre-
menopausal women (Table 2). To examine a potential dose-response for the evening group, 
the ‘Rather evening’ and ‘Definitely evening’ groups were examined separately. Risk 
estimates for ‘Definitely evening’ types (OR=3.18, 95% CI=1.25–8.07) were higher than 
‘Rather evening’ types (OR=2.24, 95% CI=0.97–5.16, Table 2). When stratified by PER3 
VNTR status, an association between BrCA risk and either morning (OR=3.83, 95% 
CI=1.50–9.81) or evening chronotype (OR=6.35, 95% CI=2.14–18.84) was observed among 
women with the 4/5 or 5/5 genotype. However, no statistically significant association was 
observed among those with the 4/4 genotype (morning OR=1.31, 95% CI=0.34–5.04; 
evening OR=0.67, 95% CI=0.16–2.80, Table 3).
Discussion
India has traditionally had some of the lowest cancer rates globally but it is undergoing rapid 
modernization with increasing BrCA incidence in urban areas. These transitions bring 
lifestyle changes that may influence BrCA risk (e.g., light-at-night exposures, altered sleep-
wake timing) (5,56). Polymorphic variation in clock genes may contribute to these impacts 
(4,5,7–10). In this exploratory analysis, the association between PER3 VNTR genotype and 
BrCA risk was generally consistent with risk estimates reported among women in the US (7) 
and China (24), where no statistically significant increased BrCA risks were observed 
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among pre- and post-menopausal women combined. In the US, the 5-repeat PER3 genotype 
was more common among premenopausal BrCA cases relative to controls (OR=1.7, 95% 
CI=1.0–3.0) (7), whereas the 43% increased odds of a 5-repeat genotype among 
premenopausal BrCA cases in the present study did not achieve statistical significance 
(Table 2).
BrCA cases in the present study were more likely to have a morning or evening chronotype 
relative to controls. Chronotype may influence circadian biological processes relevant to 
BrCA in a manner similar to what occurs among shiftworkers (40–42). By analogy, 
endogenous sleep-wake timing among those with extreme chronotype can be 
desynchronized with social or environmental cues, resulting in inappropriately timed light 
exposures, clock gene dysregulation, sleep loss, fatigue, and endocrine or immune system 
perturbations similar to those encountered among shiftworkers. Disruption of these 
processes may facilitate carcinogenesis. Shiftwork has been associated with several cancers 
including BrCA (44,57–65), and the relationship may be modified by chronotype (40–
42,44). The potential health-related impacts associated with eveningness are generally 
considered more severe relative to morningness (e.g., sleep loss, fatigue, depression, 
hypertension, type 2 diabetes) (30–32). However, morningness has been associated with: 
sleep disruption, physical inactivity, fatigue, lipid dysregulation, weight gain, and shiftwork 
intolerance (32–39,43,56). A recent study found that morning types who worked nights had 
BrCA risk estimates that were almost double those observed among evening types working 
nights (44). Others have found no associations between BrCA and extreme chronotype, or 
chronotype combined with shiftwork or sleep duration (45,46). Discrepancies among these 
studies may stem from the timing or type of chronotype assessment used, unexplored 
chronotype characteristics (e.g., bimodal chronotypes), or mediating factors (e.g., 
chronotype adaptation strategies). Both chronotype extremes have established differences in 
intrinsic circadian period length and other diurnal physiological processes (5,25,29). Urban 
environments may foster social jetlag or other perturbations among those with extreme 
chronotype as individuals transition between weekdays and weekends (66). Additional 
research is needed to examine the extent to which chronotype, possibly in combination with 
social desynchronization, may contribute to carcinogenesis.
Several strengths and limitations of this study are noteworthy. It is possible that 
psychological or physiological side effects of a cancer diagnosis may have altered cancer 
patient’s self-identification with chronotype, thus resulting in exposure misclassification. To 
reduce potential recall bias, the interview targeted the year prior to diagnosis as the reporting 
timeframe. There were no differences in chronotype among BrCA cases with differing levels 
of disease severity (e.g., tumor grade, nodal involvement) or by time between diagnosis and 
recruitment, which suggests that BrCA diagnosis did not impact chronotype reporting. 
Chronotype was assessed using only two questions. These items were internally consistent; 
morning types woke earlier (5:34AM±55 minutes vs. 6:04AM±70 minutes, respectively, 
p<0.01) and went to bed earlier compared to evening types (10:45PM±62 minutes vs. 
11:08PM±64 minutes, respectively, p<0.01), and the results in relation to BrCA were similar 
using either item. Single questions assessing diurnal preference have been well-correlated 
with more comprehensive scales (25,26,42). The PER3 VNTR was not in HWE, thus 
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limiting generalizability of findings. However, the frequencies were similar to those 
observed in previous studies, and quality control for the genotyping was acceptable. 
Interpretation of the results is limited by the sample sizes among morning types or within 
strata of menopausal status. Nonetheless, evidence for dose-response was observed among 
women with increasing degrees of evening preference. The analysis accounted for most 
known or suspected BrCA risk factors and factors that differed between cases and controls.
When combined with the 4/5 or 5/5 PER3 genotype, extremes in chronotype were 3.8–6.4 
times more likely to be associated with BrCA risk, whereas no statistically significant 
associations were observed among those with the 4/4 genotype. These observations are 
consistent with the possibility that chronotype and BrCA susceptibility may arise from one 
or more common genetic traits. The 4/4 and 5/5 PER3 genotypes have been previously 
associated with eveningness and morningness, respectively (19–21), although others have 
found no association (22,23), consistent with the current analysis. The PER3 VNTR does 
not necessarily ‘re-create’ the complexity of chronotype (19), and other polymorphisms also 
have been associated with this trait (4). Thus, the heritable component of chronotype may be 
polygenic and several gene variants may be needed for its full phenotypic expression 
(22,67). The 5/5 PER3 VNTR may be more strongly coupled to circadian processes than the 
4/4 genotype (18,68). If so, 5-repeat variants may be more susceptible to factors that elicit 
circadian disruption or clock gene dysregulation, such as altered sleep-wake timing, an 
inherent aspect of chronotype. The 5-repeat sequence adds several potential phosphorylation 
motifs to the PER3 gene. Modification of phosphorylation sites in PER genes can alter sleep 
homeostasis or circadian hormone secretion (9,18), and may also increase cancer 
susceptibility. For example, a mutated PER2 phosphorylation site is linked with familial 
advanced sleep phase syndrome (FASPS) (69), an extreme form of morningness (70). 
Transgenic insertion of this mutation into mice recapitulated a morningness (advanced 
phase) phenotype, and elicited cancer-prone characteristics, including reduced apoptosis and 
survival following gamma-irradiation in vivo (71), and increases in tumor foci in vitro (72). 
The PER3 gene exhibits tumor suppressor properties; its expression is reduced in breast 
tumors relative to normal tissue (11–13), and its deletion from breast tumors predicts BrCA 
recurrence and reduced survival (16). In mice, Per3 deletion increases mammary tumor 
susceptibility (16).
In conclusion, results from this study suggest a relationship between chronotype and BrCA; 
an association that is enhanced among women with the 5-repeat PER3 genotype. There are 
some inconsistencies among studies conducted to date, and the underlying mechanism 
awaits further characterization. Thus, cautious interpretation of this exploratory study is 
advised pending additional research. The National Center of Sleep Disorders Research has 
expressed a need for surrogate measures of sleep and circadian physiology that can be 
readily implemented in population-based studies of chronic disease (73). Chronotype is a 
simple, reliable and valid measure that may help elucidate the potential relationship between 
circadian rhythm disruption and BrCA risk in areas where recent modernization may 
facilitate increased BrCA risk, such as India, or in populations with racial cancer disparities 
and inherent differences in endogenous circadian timing (74,75).
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Table 2











    4/4 85 (37%) 81 (38%) 1.0 (Referent) 1.0 (Referent)
   4/5 + 5/5 144 (63%) 131 (62%) 1.05 (0.71–1.54) 1.33 (0.83–2.14)
Chronotype
   Morning 158 (62%) 151 (61%) 1.20 (0.69–2.11) 2.43 (1.23–4.81)
  No Preference 27 (11%) 31 (12%) 1.0 (Referent) 1.0 (Referent)
   Evening 68 (27%) 67 (27%) 1.17 (0.63–2.16) 2.55 (1.19–5.47)
Premenopausal Women (n=259)
PER3 VNTR
    4/4 43 (36%) 45 (41%) 1.0 (Referent) 1.0 (Referent)
   4/5 + 5/5 75 (64%) 64 (59%) 1.23 (0.72–2.09) 1.43 (0.73–2.81)
Chronotype
   Morning 75 (57%) 77 (61%) 0.75 (0.31–1.81) 1.54 (0.55–4.29)
  No Preference 13 (10%) 10 (8%) 1.0 (Referent) 1.0 (Referent)
   Evening 43 (33%) 40 (32%) 0.83 (0.33–2.10) 1.95 (0.65–5.88)
Postmenopausal Women (n=245)
PER3 VNTR
    4/4 42 (38%) 36 (35%) 1.0 (Referent) 1.0 (Referent)
   4/5 + 5/5 69 (62%) 67 (65%) 0.88 (0.51–1.54) 1.31 (0.63–2.73)
Chronotype
   Morning 83 (68%) 74 (61%) 1.68 (0.80–3.55) 4.51 (1.62–12.58)
  No Preference 14 (11%) 21 (17%) 1.0 (Referent) 1.0 (Referent)
   Evening 25 (20%) 27 (22%) 1.39 (0.58–3.31) 3.02 (0.92–9.96)
a
Analyses adjusted for: age, marital status, tobacco use, family tobacco use, waist-to-hip ratio, walking activity, income, body mass index, and 
mineral intake. Additional adjustments for Morning/Evening type included: diastolic blood pressure, mosquito repellant use; and for PER3 VNTR: 
contraceptive use, diastolic blood pressure, consanguinity, vitamin C intake. The 4/5 and 5/5 PER3 VNTR genotypes were combined due to sparse 
data. Percentages may not equal 100 due to rounding; stratum specific frequencies may not equal total number of cases or controls due to missing 
data. VNTR: variable number tandem repeat. OR: odds ratio. CI: confidence interval.
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Table 3
Relationship Between Breast Cancer Status and Chronotype, Stratified by PER3 VNTR Genotype, BRCA 








4/4 PER3 VNTR Women (n=166)
Chronotype
   Morning 51 (61%) 42 (52%) 0.88 (0.33–2.40) 1.31 (0.34–5.04)
  No Preference 11 (13%) 8 (10%) 1.0 (Referent) 1.0 (Referent)
   Evening 22 (26%) 31 (38%) 0.52 (0.18–1.49) 0.67 (0.16–2.80)
4/5+5/5 PER3 VNTR Women (n=275)
Chronotype
   Morning 90 (63%) 84 (64%) 1.43 (0.69–2.97) 3.83 (1.50–9.81)
  No Preference 15 (10%) 20 (15%) 1.0 (Referent) 1.0 (Referent)
   Evening 39 (27%) 27 (21%) 1.93 (0.84–4.42) 6.35 (2.14–18.84)
a
Includes both pre- and post-menopausal women. Analyses adjusted for: age, marital status, tobacco use, family tobacco use, waist-to-hip ratio, 
walking activity, income, body mass index, diastolic blood pressure, mosquito repellant use and mineral intake. Percentages may not equal 100 due 
to rounding; stratum specific frequencies may not equal total number of cases or controls due to missing data. VNTR: variable number tandem 
repeat. OR: odds ratio. CI: confidence interval.
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